

# Contents

|          |                                                                                                         |          |
|----------|---------------------------------------------------------------------------------------------------------|----------|
| <b>1</b> | <b>Introduction to Competitive Intelligence.....</b>                                                    | <b>1</b> |
| 1        | Definition .....                                                                                        | 1        |
| 2        | Introduction: Why Perform CI? .....                                                                     | 2        |
|          | Reference .....                                                                                         | 3        |
| 3        | Regulatory Guidance, Advisory Committee Meetings,<br>and Case Examples .....                            | 3        |
| 3.1      | Regulatory Guidance .....                                                                               | 3        |
| 3.2      | Advisory Committee Meetings .....                                                                       | 4        |
| 4        | Case Examples.....                                                                                      | 5        |
| 4.1      | Case Example I: Cardiovascular Risk.....                                                                | 5        |
| 4.1.1    | Introduction .....                                                                                      | 5        |
| 4.1.2    | QT Prolongation as a Cardiac Safety Biomarker .....                                                     | 7        |
| 4.1.3    | Regulatory History of Formalized Cardiac<br>Safety Assessment .....                                     | 7        |
| 4.1.4    | Regulatory History of Formalized Cardiovascular<br>Safety Assessment for Antidiabetic Drugs for T2DM... | 10       |
| 4.1.5    | FDA’s December 2008 Guidance for Industry.....                                                          | 12       |
| 4.1.6    | Continued Discussion in the Literature of the<br>Cardiovascular Safety of Avandia and Actos .....       | 13       |
| 4.1.7    | July 2010 FDA Advisory Committees’ Meeting<br>on Avandia.....                                           | 14       |
| 4.1.8    | EMA’s January 2010 Draft Guidance.....                                                                  | 14       |
| 4.1.9    | Potential Ramifications for Future Global<br>Development of Antidiabetic Drugs for T2DM .....           | 14       |
| 4.1.10   | Summary .....                                                                                           | 15       |
|          | References.....                                                                                         | 15       |
| 4.2      | Case Example II: Patient-Centric Services .....                                                         | 16       |
| 4.2.1    | Introduction .....                                                                                      | 16       |
| 4.2.2    | Privacy Challenges of Launching an Integrated<br>PCS Platform.....                                      | 19       |

|          |                                                                                                              |           |
|----------|--------------------------------------------------------------------------------------------------------------|-----------|
| 4.2.3    | Remote Patient Monitoring .....                                                                              | 20        |
| 4.2.4    | Regulatory Implications and Challenges .....                                                                 | 20        |
| 4.2.5    | HIPAA .....                                                                                                  | 21        |
| 4.2.6    | HITECH .....                                                                                                 | 21        |
| 4.2.7    | Social Media and HIPAA .....                                                                                 | 22        |
| 4.2.8    | 510(k) Classification .....                                                                                  | 22        |
| 4.2.9    | Health and Wellness Programs .....                                                                           | 23        |
| 4.2.10   | REMS Programs .....                                                                                          | 23        |
| 4.2.11   | Latest FDA Regulations for Mobile<br>Medical Applications .....                                              | 24        |
| 4.2.12   | Regulatory Overlap .....                                                                                     | 25        |
| 4.2.13   | Summary .....                                                                                                | 26        |
|          | References .....                                                                                             | 26        |
| 4.3      | Case Example III: Biosimilars .....                                                                          | 26        |
| 4.3.1    | EU Biosimilar Status .....                                                                                   | 27        |
| 4.3.2    | Approved Biosimilars in the EU .....                                                                         | 28        |
| 4.3.3    | Status of FOBs in America .....                                                                              | 29        |
| 4.3.4    | Interchangeability .....                                                                                     | 30        |
| 4.3.5    | Exclusivity .....                                                                                            | 30        |
| 4.3.6    | Approved Biosimilars in the USA .....                                                                        | 31        |
| 4.3.7    | Summary .....                                                                                                | 32        |
| 4.3.8    | Chemistry, Manufacturing & Controls (CMC)<br>Concerns for Biosimilars .....                                  | 32        |
| 4.3.9    | Efficacy Comparisons, Preclinical Safety,<br>Pharmacokinetics, and Clinical Studies<br>for Biosimilars ..... | 35        |
| 4.3.10   | Summary .....                                                                                                | 37        |
|          | References .....                                                                                             | 37        |
| <b>2</b> | <b>Overall Perspective of Due Diligence</b>                                                                  |           |
|          | <b>Investigations and Processes .....</b>                                                                    | <b>39</b> |
| 1        | Experience of Risk-Based Transactions .....                                                                  | 39        |
| 2        | The Process of Due Diligence .....                                                                           | 40        |
| 3        | Outcomes of Due Diligence .....                                                                              | 41        |
|          | Reference .....                                                                                              | 41        |
| <b>3</b> | <b>The Regulatory Functional Review: Primary Roles .....</b>                                                 | <b>43</b> |
| 1        | Introduction .....                                                                                           | 43        |
| 2        | Transaction Types .....                                                                                      | 44        |
| 3        | Time Commitment .....                                                                                        | 44        |
|          | Reference .....                                                                                              | 44        |
| 4        | Output and Expectations .....                                                                                | 44        |

|                                                                                                          |    |
|----------------------------------------------------------------------------------------------------------|----|
| <b>4 The On-Site Due Diligence/Data Room Meeting and Interactions with Other Functional Area Experts</b> | 47 |
| 1 Preparation                                                                                            | 47 |
| 2 The Virtual Data Room                                                                                  | 49 |
| 2.1 Types of Electronic Databases                                                                        | 49 |
| 2.2 Internet-Based Data Rooms                                                                            | 50 |
| 2.3 Advantages                                                                                           | 50 |
| 2.4 Potential Disadvantages of VDRs                                                                      | 51 |
| 3 Summary                                                                                                | 52 |
| Reference                                                                                                | 53 |
| 4 The On-Site Data Room Meeting                                                                          | 53 |
| 5 Requests of the Potential Partner                                                                      | 54 |
| 6 FDA Correspondence                                                                                     | 54 |
| 7 Preclinical Information                                                                                | 55 |
| Reference                                                                                                | 55 |
| 8 Chemistry Manufacturing Controls Information                                                           | 55 |
| 9 Clinical Information                                                                                   | 56 |
| 10 Commercial Information                                                                                | 57 |
| 11 Secondary Research                                                                                    | 60 |
| 12 Primary Market Research                                                                               | 61 |
| <b>5 Intellectual Property</b>                                                                           | 65 |
| 1 Introduction                                                                                           | 65 |
| 2 Patent Exclusivity                                                                                     | 66 |
| 3 The IP Due Diligence Process                                                                           | 67 |
| 4 Initial Due Diligence and Role of the Regulatory Affairs Professional                                  | 69 |
| 5 Role of the Patent Attorney                                                                            | 69 |
| 6 Role of the Chemistry Manufacturing Controls Expert                                                    | 70 |
| 7 Contractual Protection                                                                                 | 70 |
| 8 Regulatory Exclusivity: The US Drug Price Competition and Patent Restoration Act                       | 70 |
| 9 Case Study                                                                                             | 73 |
| 10 Summary                                                                                               | 74 |
| References                                                                                               | 74 |
| <b>6 The Final Report</b>                                                                                | 75 |
| Reference                                                                                                | 75 |
| <b>7 Competitive Intelligence Summary</b>                                                                | 77 |
| <b>About the Author</b>                                                                                  | 79 |
| <b>Index</b>                                                                                             | 81 |

Pharmaceutical Competitive Intelligence for the  
Regulatory Affairs Professional

Huml, R.A.

2012, XV, 82 p. 4 illus., 3 illus. in color., Softcover

ISBN: 978-1-4614-3681-2